Cancer's MHC I Escape Trick Backfires, Study Finds
SkimNews Take
Cancer's immune evasion strategy, by removing MHC I, inadvertently triggers a distinct immune response that could be exploited for more effective treatments.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Cancer cells that lose MHC I — a common immune-evasion tactic — become more susceptible to attack by CD4+ "helper" T cells, which trigger ferroptosis, an iron-dependent form of cell death, in those targets.
- The study, published in Nature Immunology, challenges the decades-old principle that MHC class I exclusively communicates with CD8+ "killer" T cells while MHC class II activates CD4+ T cells, identifying a previously unrecognized role for MHC I in CD4-driven immunity.
- Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, led the multi-institutional collaboration with Dr. Arul Chinnaiyan and Dr. Marcin Cieslik of the University of Michigan Rogel Cancer Center.
- The same ferroptosis vulnerability appeared in models of graft-versus-host disease, a serious complication of bone marrow transplantation, suggesting the mechanism extends beyond solid tumors to allogeneic immune responses.
- Analysis of large transcriptomic and clinical datasets from patients who received checkpoint inhibitor therapies for solid tumors showed correlations between the newly identified immune pathway and patient outcomes.
- The work was supported by NIH grants (including P01CA039542, R01HL152605, and R01CA217156) and Cancer Prevention and Research Institute of Texas grants RR220033 and RP240432.
Why it matters: For decades, tumors that downregulate MHC I have been considered largely invisible to the immune system — now researchers have shown that same loss opens a fatal vulnerability to CD4+ T cell attack, including via ferroptosis. The finding reframes a well-known cancer-evasion strategy as an Achilles' heel that future immunotherapies could exploit against the many solid tumors already resistant to CD8-targeted checkpoint inhibitors.
